Plain-English translation of NCT06704555 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment combination for people with follicular lymphoma (a type of blood cancer) who have not received any cancer treatment before and have a large tumor. The treatment combines radiation therapy with chemotherapy drugs and a new immunotherapy medication called . The goal is to see if adding this immunotherapy drug to standard chemotherapy can improve how well the treatment works.
Follicular lymphoma can be difficult to treat when tumors are large, and doctors want to find better ways to help patients achieve long-lasting remission. This trial explores whether the new immunotherapy approach can boost the effectiveness of standard cancer treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive radiation therapy to the large tumor over several weeks. About 1–2 weeks later, you will begin chemotherapy combined with , given intravenously in 6 cycles, with each cycle lasting about 3–4 weeks. During and after treatment, you will have PET/CT scans to check how well the treatment is working. If the treatment works well, you may continue to receive the immunotherapy medication every 2 months for up to 2 years to help prevent the cancer from returning.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China